Outcomes after allogeneic HCT after CD19 CAR T-cell therapy. (A-B) Kaplan-Meier analyses demonstrating EFS and OS in patients who received allogeneic HCT while in MRD-negative CR after CD19 CAR T-cell therapy (n = 18). Two-year Kaplan-Meier point estimates of EFS and OS were 61% and 72%, respectively. (C) Cumulative incidence of relapse (blue line) and NRM (green line), with 2-year estimates of 17% and 23%, respectively. Day 0 was defined as the date of allogeneic HCT.